REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis

Published:2017-03-10 Issue:12 Volume:123 Page:2294-2302
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Berry Vincent¹²,Basson Laurent³,Bogart Emilie³,Mir Olivier⁴,Blay Jean-Yves⁵,Italiano Antoine⁶,Bertucci François⁷,Chevreau Christine⁸,Clisant-Delaine Stéphanie²⁹,Liegl-Antzager Bernadette¹⁰,Tresch-Bruneel Emmanuelle³,Wallet Jennifer³,Taieb Sophie¹¹,Decoupigny Emilie²⁹,Le Cesne Axel⁴,Brodowicz Thomas¹²,Penel Nicolas¹²

Affiliation:

1. Medical Oncology Department; Oscar Lambret Center; Lille France

2. Methodology and Clinical Research Platform; SIRIC OncoLille; Lille France

3. Biostatisitics and Methodology Unit; Oscar Lambret Center; Lille France

4. Medical Oncology Department; Gustave Roussy; Villejuif France

5. Medical Oncology Department; Léon Bérard Center; Lyon France

6. Medical Oncology Department; Bergonié Institute; Bordeaux France

7. Medical Oncology Department; Paoli-Calmette Institute; Marseille France

8. Medical Oncology Department; University Cancer Institute of Toulouse-Oncopole; Toulouse France

9. Clinical Research Unit; Oscar Lambret Center; Lille France

10. Institute of Pathology; Medical University of Graz; Graz Austria

11. Radiology Department; Oscar Lambret Center; Lille France

12. General Hospital; Medical University of Vienna; Vienna Austria

Funder

Bayer HealthCare SA

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30661/fullpdf

Reference13 articles.

1. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing;Ducimetiere;PLoS One.,2011

2. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;ESMO/European Sarcoma Network Working Group;Ann Oncol,2014

3. Trends in survival for patients with metastatic soft-tissue sarcoma;Italiano;Cancer.,2011

4. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study;Garcia-Del-Muro;J Clin Oncol.,2011

5. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial;Mir;Lancet Oncol.,2016

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review;Critical Reviews in Oncology/Hematology;2024-05

2. Augmenting Cancer Therapy with a Supramolecular Immunogenic Cell Death Inducer: A Lysosome-Targeted NIR-Light-Activated Ruthenium(II) Metallacycle;Journal of the American Chemical Society;2024-03-21

3. Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy;Scientific Reports;2023-07-03

4. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study;Anti-Cancer Drugs;2023-03-24

5. Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma;Frontiers in Oncology;2023-01-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3